Immorna Biotherapeutics, Inc.
Clinical trials sponsored by Immorna Biotherapeutics, Inc., explained in plain language.
-
New shingles vaccine shows promise in Head-to-Head trial
Vaccine OngoingThis study tests a new shingles vaccine called JCXH-105 in healthy adults aged 50 and older. It compares the new vaccine to the current standard, Shingrix, to see if it is safe and triggers a strong immune response. About 467 participants will receive either JCXH-105 or Shingrix,…
Phase 2 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC
-
New mRNA vaccine aims to shield older adults from RSV
Vaccine OngoingThis early-stage study tests an experimental mRNA vaccine called JCXH-108 to see if it is safe and triggers an immune response against RSV, a common respiratory virus. About 75 healthy volunteers, split into two age groups (18-45 and 60+), will receive either the vaccine or a pla…
Phase 1 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC